JYNT241220P20000
- 0.00
- 0.000.00%
The Joint Newsroom
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
The Joint Commission and the National Association for Healthcare Quality Form Strategic Alliance to Advance Global Patient Safety and Healthcare Quality
JLL and Slate Asset Management Announce Technology Joint Venture to Tackle Data Challenges for Real Estate Investors
People With Parkinson's Disease (PD) Face Disproportionate Rates of Harm in Hospital Setting
JYNT's Q3 Earnings Meet Estimates Amid Higher Costs, Shares Dip 3%
The Joint Commission Issues Sentinel Event Alert to Help Prepare Healthcare Organizations for Environmental Disasters
ABMS Portfolio Program Featured in The Joint Commission Journal on Quality and Patient Safety
The Joint Corp. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Joint Price Target Cut to $15.00/Share From $16.00 by Roth MKM
Joint Analyst Ratings
The Joint | 10-Q: Q3 2024 Earnings Report
Lake Street Maintains The Joint(JYNT.US) With Buy Rating, Maintains Target Price $20
Roth MKM Maintains The Joint(JYNT.US) With Buy Rating, Cuts Target Price to $15
The Joint Corp (JYNT) Q3 2024 Earnings Call Highlights: Navigating Growth Amid Economic Headwinds
The Joint Corp. Reports Mixed Q3 2024 Results
Joint Q3 2024 Adj. EPS $0.04 Beats $0.01 Estimate, Sales $30.198M Beat $28.376M Estimate
The Joint Corp. (JYNT) Q3 Earnings Match Estimates
Express News | Joint Corp. FY 2024 System-wide Sales Are Expected to Be Between $525 Million and $535 Million
Earnings Flash (JYNT) THE JOINT Posts Q3 Revenue $30.2M
Joint GAAP EPS of -$0.21 Misses by $0.22, Revenue of $30.19M Beats by $1.81M